Defining Strategies for Improving Endothelial and Fibrinolytic Dysfunction in Obesity
Primary Purpose
Metabolic Syndrome X
Status
Terminated
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Eplerenone
Ramipril
Sponsored by
About this trial
This is an interventional prevention trial for Metabolic Syndrome X focused on measuring Fibrolytic Dysfunction, Obesity, PAI-1
Eligibility Criteria
Inclusion Criteria:
- Male or females between the ages of 18 to 65 years of age.
- Documented diagnosis for the metabolic syndrome:
- Subjects with hypertension (SP>130mmHg)
- Subjects with central obesity (females waist >35"; males waist >40")
- Subjects with dyslipidemia (HDL <40mg/dl, triglycerides > 150 mg/dl)
- Subjects who are insulin resistance (fasting glucose >100mg/dl)
Exclusion Criteria:
- Subjects who smoke
- Women who are pregnant (confirmed by urine beta-HCG).
- Women who are breast feeding
Subjects with documentation of the following health risk:
- Subjects with serum creatinine >2.0 mg/dl (males), >1.8 mg/dl (females)
- Subjects whose creatinine clearance < 50 mls/min
- Subjects with serum potassium >5.5mEql
- Subjects with Type 2 diabetes with microalbuminuria (spot urine protein/creatinine ration >0.2)
- Subjects who are currently taking the following medications:
- Warfarin
Sites / Locations
- Vanderbilt University Medical Center
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
Treatment A
Treatment B
Arm Description
Eplerenone (study drug)
Ramipril
Outcomes
Primary Outcome Measures
Secreted Factors From Adipocytes Have Autocrine, Paracrine and Endocrine Effects That Have a Deleterious Effect on the Fibrinolytic System, Either by Enhancing PAI-1 Production or Impairing Endothelial t-PA Release
This Study Will Analyze Patients' Genetic Make up to Identify Who May be at Greater Risk for Heart Disease and Strokes in Relationship to High Blood Pressure and Central Obesity.
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00608465
Brief Title
Defining Strategies for Improving Endothelial and Fibrinolytic Dysfunction in Obesity
Official Title
Defining Strategies for Improving Endothelial and Fibrinolytic Dysfunction in Obesity
Study Type
Interventional
2. Study Status
Record Verification Date
July 2017
Overall Recruitment Status
Terminated
Why Stopped
Lack of enrollment
Study Start Date
May 2006 (Actual)
Primary Completion Date
May 2009 (Actual)
Study Completion Date
May 2011 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Vanderbilt University
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The combination of high blood pressure and having central obesity is an increasing important factor for heart disease in men and women. It can also lead to the early development of hardening of the arteries and increased risk of a stroke. This study will analyze patients' genetic make up to identify who may be at greater risk for heart disease and strokes in relationship to high blood pressure and central obesity.
Detailed Description
Obesity is an increasingly important risk factor for cardiovascular disease in men and women and is associated with the premature development of atherosclerosis, and increased risk of stroke. A classical perspective of cardiovascular risk does not adequately explain all of the cardiovascular events associated with obesity. Elevated plasma levels of plasminogen activator inhibitor type I (PAI-1) are one of the biochemical hallmarks for obesity and likely contribute the increased risk of atherothrombotic events in patients with obesity. The central hypothesis of this proposal is that the increased risk of atherothrombotic events in patients with obesity. The central hypothesis of this proposal is that vascular PAI-1 excess promotes the development of intravascular thrombosis. We will test the hypothesis that secreted factors from adipocytes have autocrine, paracrine and endocrine effects that have a deleterious effect on the fibrinolytic system, either by enhancing PAI-1 production or impairing endothelial t-PA release. From a public health perspective, there is no greater threat to America's cardiovascular health than the epidemic of obesity. It is anticipated that this study will provide new insights nto the molecular mechanisms that contribute to the development of fibrinolytic dysfunction and cardiovascular disease in obesity.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Metabolic Syndrome X
Keywords
Fibrolytic Dysfunction, Obesity, PAI-1
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
4 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Treatment A
Arm Type
Active Comparator
Arm Description
Eplerenone (study drug)
Arm Title
Treatment B
Arm Type
Active Comparator
Arm Description
Ramipril
Intervention Type
Drug
Intervention Name(s)
Eplerenone
Other Intervention Name(s)
Inspra
Intervention Description
5 mg x 1 week followed by 10 mg x 9 weeks.
Intervention Type
Drug
Intervention Name(s)
Ramipril
Intervention Description
Ramipril 5mg qd x 1 week f/b Ramipril qd x 9 weeks.
Primary Outcome Measure Information:
Title
Secreted Factors From Adipocytes Have Autocrine, Paracrine and Endocrine Effects That Have a Deleterious Effect on the Fibrinolytic System, Either by Enhancing PAI-1 Production or Impairing Endothelial t-PA Release
Time Frame
10-Week period
Title
This Study Will Analyze Patients' Genetic Make up to Identify Who May be at Greater Risk for Heart Disease and Strokes in Relationship to High Blood Pressure and Central Obesity.
Time Frame
10-weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Male or females between the ages of 18 to 65 years of age.
Documented diagnosis for the metabolic syndrome:
Subjects with hypertension (SP>130mmHg)
Subjects with central obesity (females waist >35"; males waist >40")
Subjects with dyslipidemia (HDL <40mg/dl, triglycerides > 150 mg/dl)
Subjects who are insulin resistance (fasting glucose >100mg/dl)
Exclusion Criteria:
Subjects who smoke
Women who are pregnant (confirmed by urine beta-HCG).
Women who are breast feeding
Subjects with documentation of the following health risk:
Subjects with serum creatinine >2.0 mg/dl (males), >1.8 mg/dl (females)
Subjects whose creatinine clearance < 50 mls/min
Subjects with serum potassium >5.5mEql
Subjects with Type 2 diabetes with microalbuminuria (spot urine protein/creatinine ration >0.2)
Subjects who are currently taking the following medications:
Warfarin
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
James AS Muldowney, MD
Organizational Affiliation
Vanderbilt University Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Vanderbilt University Medical Center
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37232
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Defining Strategies for Improving Endothelial and Fibrinolytic Dysfunction in Obesity
We'll reach out to this number within 24 hrs